Immunogenicity 462

summary
Sample ID
None
Response
Negative
Tumor Type
Melanoma
Gene Symbol
KCNC3
Transcript ID
None
HLA INFO
A*03:01
TCR INFO

No TCR info found!

T cell Tumor cell A*03:01
sequence
Full length protein sequence (757 aa)
MLSSV
1
CVSSF
6
RGRQG
11
ASKQQ
16
PAPPP
21
QPPES
26
PPPPP
31
LPPQQ
36
QQPAQ
41
PGPAA
46
SPAGP
51
PAPRG
56
PGDRR
61
AEPCP
66
GLPAA
71
AMGRH
76
GGGGG
81
DSGKI
86
VINVG
91
GVRHE
96
TYRST
101
LRTLP
106
GTRLA
111
GLTEP
116
EAAAR
121
FDYDP
126
GADEF
131
FFDRH
136
PGVFA
141
YVLNY
146
YRTGK
151
LHCPA
156
DVCGP
161
LFEEE
166
LGFWG
171
IDETD
176
VEACC
181
WMTYR
186
QHRDA
191
EEALD
196
SFEAP
201
DPAGA
206
ANAAN
211
AAGAH
216
DGGLD
221
DEAGA
226
GGGGL
231
DGAGG
236
ELKRL
241
CFQDA
246
GGGAG
251
GPPGG
256
AGGAG
261
GTWWR
266
RWQPR
271
VWALF
276
EDPYS
281
SRAAR
286
YVAFA
291
SLFFI
296
LISIT
301
TFCLE
306
THEGF
311
IHISN
316
KTVTQ
321
ASPIP
326
GAPPE
331
NITNV
336
EVETE
341
PFLTY
346
VEGVC
351
VVWFT
356
FEFLM
361
RITFC
366
PDKVE
371
FLKSS
376
LNIID
381
CVAIL
386
PFYLE
391
VGLSG
396
LSSKA
401
AKDVL
406
GFLRV
411
VRFVR
416
ILRIF
421
KLTRH
426
FVGLR
431
VLGHT
436
LRAST
441
NEFLL
446
LIIFL
451
ALGVL
456
IFATM
461
IYYAE
466
RIGAD
471
PDDIL
476
GSNHT
481
YFKNI
486
PIGFW
491
WAVVT
496
MTTLG
501
YGDMY
506
PKTWS
511
GMLVG
516
ALCAL
521
AGVLT
526
IAMPV
531
PVIVN
536
NFGMY
541
YSLAM
546
AKQKL
551
PKKKN
556
KHIPR
561
PPQPG
566
SPNYC
571
KPDPP
576
PPPPP
581
HPHHG
586
SGGIS
591
PPPPI
596
TPPSM
601
GVTVA
606
GAYPA
611
GPHTH
616
PGLLR
621
GGAGG
626
LGIMG
631
LPPLP
636
APGEP
641
CPLAQ
646
EEVIE
651
INRAD
656
PRPNG
661
DPAAA
666
ALAHE
671
DCPAI
676
DQPAM
681
SPEDK
686
SPITP
691
GSRGR
696
YSRDR
701
ACFLL
706
TDYAP
711
SPDGS
716
IRKAT
721
GAPPL
726
PPQDW
731
RKPGP
736
PSFLP
741
DLNAN
746
AAAWI
751
SP
756
Mutation Information
DNA mutation:
None
Peptide Range:
714 ~ 736
Mut AA position:
715 (2 in Wild Type peptide)
Alignment
Wild Type:
"----------APSPDGSIRK---
|.||||||||
Mutant:
DRASFLLTDYALSPDGSIRKATG"
reference

Nature, 2017

An immunogenic personal neoantigen vaccine for patients with melanoma

Gene Name (from Reference) KCNC3

clinic trial
Checkpoint Blockade

None

ACT

None

Vaccination

None

Curative Effect

None

experiment
minimal_peptide

None

Antigen Type

peptide

T-cell Source

PBMCs

APC Type

autologous APCs

Assay

IFNg ELISPOT assay